Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus


Suitable animal models of human Type 1 (insulin-dependent) diabetes mellitus have long been sought, in particular a model that would permit detailed histological and immunological investigation of changes in the islet preceding the metabolic disorder. This would allow hypotheses as to pathogenesis of the condition to be examined and interventions such as immunotherapy to be tested. The most widely studied models include the low-dose streptozotocin induced diabetic mouse and the BB rat, but both differ in important respects from the human disease. In this review we describe one highly successful model, the non obese diabetic mouse. Selected aspects of pathogenesis and immunotherapy are presented and analogies with human Type 1 diabetes discussed.


  1. 1.

    Tochino Y (1986) Discovery and breeding of the NOD mouse. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — lessons from the NOD mouse. Academic Press, New York London, pp 3–10

  2. 2.

    Ohneda A, Kobayashi T, Nihei J, Tochino Y, Kanaya H, Makino S (1984) Insulin and glucagon in spontaneously diabetic nonobese mice. Diabetologia 27: 460–463

  3. 3.

    Kolb H (1987) Mouse models of insulin dependent diabetes: lowdose streptozotocin-induced diabetes and nonobese diabetic (NOD) mice. Diab Metab Rev 3: 751–778

  4. 4.

    Tochino T (1987) The NOD mouse as a model of Type 1 diabetes. CRC Crit Rev Immunol 8: 49–81

  5. 5.

    Komeda K, Goto N (1986) Genetic monitoring of the NOD mouse. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — Lessons from the NOD mouse. Academic Press New York London, pp 11–22

  6. 6.

    Makino S, Hayashi Y (1986) Genetic analysis for insulitis in the NOD mouse. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — lessons from the NOD mouse. Academic Press, New York London, pp 23–31

  7. 7.

    Wicker LS, Miller BJ, Coker LZ, McNally SE, Scott S, Mullen Y, Appel MC (1987) Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse. J Exp Med 165: 1639–1654

  8. 8.

    Prochazka M, Leiter EH, Serreze DV, Coleman DL (1987) Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science 237: 286–289

  9. 9.

    Nishimoto H, Kikimoto T, Yamamura KI, Kishimoto T (1987) Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice. Nature 328: 432–444

  10. 10.

    Boitard C, Bendelac A, Richard MF, Bach JF (1988) Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci USA 85: 9719–9723

  11. 11.

    Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE, Ryder LP, Nielsen LS, Thomsen M, Svejgaard A (1974) HLA antigens and diabetes mellitus. Lancet II: 864–866

  12. 12.

    Lernmark Å, Li S, Baekkeskov S, Christie M, Michelsen B, Ursing J, Olsson ML, Sundkvist G (1987) Islet-specific immune mechanisms. Diab Metab Rev 3: 959–980

  13. 13.

    Todd JA, Bell JI, McDevitt HO (1987) HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329: 599–604

  14. 14.

    Barnett AH, Eff C, Leslie RDG, Pyke DA (1981) Diabetes in identical twins. Diabetologia 20: 87–93

  15. 15.

    Johnston C, Pyke DA, Cudworth AG, Wolf E (1983) HLA-DR typing in identical twins with insulin-dependent diabetes: differences between concordant and discordant pairs. Br Med J 286: 253–255

  16. 16.

    Wolf E, Spencer KM, Cudworth AG (1983) The genetic susceptibility to Type 1 (insulin-dependent) diabetes analysis of the HLA-DR association. Diabetologia 24: 224–230

  17. 17.

    Leiter EH, Prochazka M, Coleman DL (1987) Animal model of human disease — the non-obese diabetic mouse. Am J Pathol 128: 380–383

  18. 18.

    Ogawa M, Maruyama T, Hasegawa T, Kanaya T, Kobayashi F, Tochino Y, Uda H (1985) The inhibitory effect of neonatal thymectomy on the incidence of insulitis in non-obese diabetes (NOD) mice. Biomed Res 6: 103–105

  19. 19.

    Nakajima H, Tarui S, Tochino Y (1986) Clues to the pathogenesis of diabetes in the NOD mouse based on preventive approaches. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — lessons from the NOD mouse. Academic Press, New York London, pp 181–186

  20. 20.

    Maclaren NK (1988) How, when and why to predict IDDM. Diabetes 37: 1591–1594

  21. 21.

    Fujita T, Yui R, Kusumoto Y, Serizawa Y, Makino S, Tochino (1982) Lymphocytic insulitis in a non-obese diabetic (NOD) strain of mice: an immunohistochemical and electron microscope investigation. Biomed Res 3: 429–443

  22. 22.

    Fujino-Kurihara M, Fujita H, Hakura A, Nonaka T, Tarui S (1985) Morphological aspects on pancreatic islets of non-obese diabetic (NOD) mice. Virchows Arch B 49: 107–120

  23. 23.

    Signore A, Cooke A, Pozzilli P, Butcher G, Simpson E, Beverley PCL (1987) Class II and IL2 receptor positive cells in the pancreas of NOD mice. Diabetologia 30: 902–905

  24. 24.

    Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Fujino-Kurihara H, Nakajima H, Nonaka K, Tarui S (1985) Predominance of T lymphocytes in pancreatic islets and spleen of prediabetic non obese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol 60: 622–630

  25. 25.

    Signore A, Gale EAM, Andreani D, Beverley PCL, Pozzilli P (1989) The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 32: 282–289

  26. 26.

    Kanazawa Y, Komeda K, Sato S, Mori S, Akanuma K, Takaku F (1984) Non-obese-diabetic mice: immune mechanisms of pancreatic B-cell destruction. Diabetologia 27: 113–115

  27. 27.

    Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14: 619–633

  28. 28.

    Gepts W (1987) Islet morphologic changes in diabetes. Diab Metab Rev 3: 859–872

  29. 29.

    Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in Type 1 (insulin-dependent) diabetes mellitus: a 25-year review of death in patients under 20 years of age in the United Kingdom. Diabetologia 29: 267–274

  30. 30.

    Bottazzo GF, Dean BM, McNally J, Hackay EH, Swift PGF, Gamble DR (1985) In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313: 353–360

  31. 31.

    Miyagawa J, Hanafusa T, Miyazaki A, Yamada K, Fujino-Kurihara H, Nakajima H, Kono N, Nonaka K, Tochino Y, Tarui S (1986) Ultrastructural and immunocytochemical aspects of lymphocytic submandibulitis in the non-obese diabetic (NOD) mouse. Virchows Arch B 51: 215–225

  32. 32.

    Asamoto H, Oishi M, Akazawa Y, Tochino Y (1986) Histological and immunological changes in the thymus and other organs in NOD mice. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — lessons from the NOD mouse. Academic Press, New York London, pp 61–71

  33. 33.

    Eisenbarth GS, Rassi N (1983) The polyglandulare failure syndromes. In: Davis TF (ed) Autoimmune endocrine disease. John Wiley & Sons, New York, pp 193–206

  34. 34.

    Reddy S, Bibby NJ, Elliot RB (1988) Ontogeny of islet cell antibodies, insulin autoantibodies and insulitis in the non-obese diabetic mouse. Diabetologia 31: 322–328

  35. 35.

    Pontesilli O, Carotenuto P, Gazda LS, Pratt PF, Prowse SJ (1987) Circulating lymphocyte populations and autoantibodies in nonobese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol 70: 84–93

  36. 36.

    Atkinson MA, MacLaren NK (1988) Autoantibodies in nonobese diabetic mice immunoprecipitate 64,000-Mr islet antigen. Diabetes 37: 1587–1590

  37. 37.

    Bendelac A, Carnaud C, Boitard C, Bach JF (1987) Syngenic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. J Exp Med 166: 823–832

  38. 38.

    Miller BJ, Appel MC, O'Neil JJ, Wicker LS (1988) Both the Lyt- 2+ and L3T4+T cell subset are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 140: 52–58

  39. 39.

    Wicker LS, Miller BJ, Mullen Y (1986) Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 35: 855–860

  40. 40.

    Harada M, Makino S (1986) Immunological manipulation of diabetes production in NOD mice. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and type I diabetes — lessons from the NOD mouse. Academic press, New York London, pp 143–153

  41. 41.

    Maruyama T, Takei I, Taniyama M, Katoaka K, Matsuki S (1984) Immunological aspect of non-obese diabetic mice: immune islet cell killing mechanism and cell-mediated immunity. Diabetologia 27: 121–123

  42. 42.

    Koike T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S (1987) Preventive effect of monoclonal anti- L3T4 antibody on development of diabetes in NOD mice. Diabetes 36: 539–541

  43. 43.

    Wang Y, Hao L, Gill RG, Lafferty KJ (1987) Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 36: 535–538

  44. 44.

    Charlton B, Bacelj A, Mandel TE (1988) Administration of silica particles or anti-Lyt2 antibody prevents beta-cell destruction in NOD mice given cyclophosphamide. Diabetes 37: 930–935

  45. 45.

    Harada M, Makino S (1984) Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27: 604–606

  46. 46.

    Bosi E, Todd I, Pujol-Borrell R, Bottazzo GF (1987) Mechanisms of autoimmunity: relevance to the pathogenesis of Type I diabetes. Diabetes Metab Rev 3: 893–928

  47. 47.

    Foulis AK, Farquharson MA, Hardman R (1987) Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30: 333–343

  48. 48.

    Hanafusa T, Fujino-Kurihara H, Miyazaki A, Yamada K, Nakajima H, Miyagawa J, Kono N, Tarui S (1987) Expression of class II major histocompatibility complex antigens on pancreatic B cells in the NOD mouse. Diabetologia 30: 104–148

  49. 49.

    Momburg F, Koch N, Moller P, Moldenhauser G, Butcher G, Hammerling GJ (1986) Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol 136: 940–948

  50. 50.

    Kida K, Kaino Y, Miyagawa T, Gotoh Y, Matsuda H, Kono T (1986) Effect of cyclosporin on insulitis and ICSA in NOD mice. In: Tarui S, Tochino Y, Nonaka K (eds) Insulitis and Type 1 diabetes — lessons from the NOD mouse. Academic Press, New York London, pp 137–142

  51. 51.

    Formby B, Miller N, Garret R, Peterson CM (1987) Effects of low-dose cyclosporine prophylaxis in nonobese diabetic mice. J Pharm Exp Ther 241: 1106–1111

  52. 52.

    Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S (1982) Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis — an observation in non obese diabetic (NOD) mice. Diabetes 31: 749–753

  53. 53.

    Nakajima H, Yamada K, Hanafusa T, Fujino-Kurihara H, Miyagawa J, Miyazaki A, Saito R, Minami Y, Kono N, Nonaka Tochino Y, Tarui S (1986) Elevated antibody-dependent cellmediated cytotoxicity and its inhibition by nicotinamide in the diabetic NOD mouse. Immunol Lett 12: 91–94

  54. 54.

    Nomikos IN, Prows SJ, Carotenuto P, Lafferty KJ (1986) Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35: 1302–1304

  55. 55.

    Vague P, Vialettes B, Lassman-Vague V, Vallo J (1987) Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet I: 619–620

  56. 56.

    Mendola G, Casamitjana R, Gomis R (1989) Effect of nicotinamide therapy upon B-cell function in newly diagnosed Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 160–162

  57. 57.

    Pozzilli P, Visalli N, Ghirlanda G, Manna R, Andreani D (1989) Nicotinamide increases C peptide secretion in patients with newly-diagnosed Type 1 (insulin-dependent) diabetes. Diabetic Med 6: 568–572

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lampeter, E.F., Signore, A., Gale, E.A.M. et al. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32, 703–708 (1989). https://doi.org/10.1007/BF00274528

Download citation

Key words

  • Non obese diabetic (NOD) mouse
  • pathogenesis Type 1 (insulin-dependent) diabetes mellitus
  • immunotherapy Type 1 diabetes